Cytovale Secures $100 Million To Expand IntelliSep In Emergency Departments
Cytovale® raises $100M in Series D funding to enhance IntelliSep, a diagnostic for early sepsis detection.
Breaking News
Oct 11, 2024
Mrudula Kulkarni

Cytovale®, a commercial-stage medical diagnostics firm focused on improving early detection technologies for fast-moving and immune-mediated diseases, has announced the successful raising of $100 million in Series D funding, led by Sands Capital. This funding also included participation from new investor Canada Pension Plan Investment Board (CPP Investments), and existing backers such as Norwest Venture Partners, Global Health Investment Corporation, and Breakout Ventures, an early supporter of the company.
"Sepsis is the largest single condition presenting to the Emergency Department where there hasn't been an effective diagnostic to quickly and effectively triage patients. Cytovale's IntelliSep test has now been demonstrated, prospectively, to help save lives and money by doing just that. We're excited to lead this financing and help accelerate Cytovale's commercial launch." said Parker Cassidy, partner at Sands Capital.
Cytovale plans to use the funds to enhance its early clinical achievements and expand the commercial reach of IntelliSep, aiming to implement it in more hospital emergency departments (EDs) and health systems across the country. IntelliSep is the first and only FDA-cleared cellular host diagnostic specifically designed for use in the ED, where over 80% of sepsis cases are identified. The test takes approximately eight minutes and offers clinicians unexampled insight into the biological factors contributing to sepsis. This allows the care teams to make diagnoses quickly and accurately and provide appropriate, patient-centred treatment.
"Seeing sepsis is a major breakthrough; IntelliSep allows our care teams in the Emergency Department to quickly and accurately triage and diagnose suspected infection patients and put them on the right path for treatment. The meaningful clinical, operational and financial benefits we have experienced have led us to implement IntelliSep across all major hospitals in our health system," said Dr. Christopher Thomas, chief quality officer of Franciscan Missionaries of Our Lady Health System.
Launched in August 2023 at Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, IntelliSep has shown promising results. The hospital reported that the screening process driven by IntelliSep enabled earlier detection of occult sepsis, leading to treatment being initiated over 60 minutes sooner. In addition, the hospital observed a 30% reduction in the risk-adjusted mortality index for sepsis patients. From a financial and operational standpoint, patients tested with IntelliSep spent an average of 1.28 fewer days in the hospital, resulting to a cost saving of $1,400 per patient.
"Sepsis has historically been one of the most challenging and costly conditions for hospitals to manage due to the lack of rapid, objective diagnostic tools. Thankfully, that's finally changing with IntelliSep, which holds the potential to transform sepsis care in the same way troponin tests did for cardiac care and rapid CT scans did for stroke diagnosis," said Cytovale CEO Ajay Shah, PhD. Cytovale is growing at an astounding pace to meet demand from other health systems looking to tackle this deadly condition. The additional investment will enable us to quickly scale across the U.S. with greater agility to serve health systems and their patients."